Vevo 1100This product is being discontinued.
Dear Valued Customer,
At FUJIFILM VisualSonics Inc. (FF-VSI), we are committed to providing the highest quality products and services to our customers. The Vevo 1100 Imaging System is being discontinued. All technology products eventually reach the end of their useful life, requiring a difficult decision to discontinue them. Product discontinuation is a part of the cycle that drives new technology and product innovation. Today, we continue to offer our customers the robust Vevo 3100 and the Vevo LAZR-X Imaging Solutions for your preclinical imaging needs. See product retirement information.
Ultra High-frequency Ultrasound, Designed Specifically for Preclinical Cardiac Researchers
The Vevo® 1100 Imaging System is VisualSonics' entry-level ultra high-frequency ultrasound system designed to perform basic cardiovascular studies and to meet both your research and budgetary needs.
The Vevo 1100 offers real-time, in vivo physiological information that contributes to understanding the function of the heart. The software is intuitive and allows quick calculations of cardiac function and structure. With resolution down to 30 µm, you can even see intima media thickness to quantify vascular and valvular disease.
The Unique Configuration of the Vevo 1100 Includes the Following Features:
Additional options include:
- Vevo Imaging Station for stabilization of the transducer and subject animal
- Includes ECG, heart rate, respiration and temperature monitoring
- Leasing options available
Applications related to the Vevo 1100
Downloaded or access resources related to Vevo 1100
Learn more about the Vevo 1100 by attending one of our courses, webinars or events.
Publications related to the Vevo 1100
MiR-135b protects cardiomyocytes from infarction through restraining the NLRP3/caspase-1/IL-1β pathway
Proline improves cardiac remodeling following myocardial infarction and attenuates cardiomyocyte apoptosis via redox regulation
Modulatory effect of metformin on cardiotoxicity induced by doxorubicin via the MAPK and AMPK pathways
Formononetin ameliorates myocardial ischemia/reperfusion injury in rats by suppressing the ROS-TXNIP-NLRP3 pathway
Thank you for your patience. Your search results are loading.